The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats

Muscle contraction increases the in vivo structural strength to the same degree in osteopenic and normal rat tibiae

(2010) Lars Nordsletten et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)α agonist fenofibrate and the PPARγ agonist pioglitazone

(2009) Unni Syversen et al.   BMC Endocrine Disorders

The PPARgamma-selective ligand BRL-49653 differentially regulates the fate choices of rat calvaria versus rat bone marrow stromal cell populations

(2008) Takuro Hasegawa et al.   BMC DEVELOPMENTAL BIOLOGY

Activation of peroxisome proliferator-activated receptor γ inhibits TNF-α-mediated osteoclast differentiation in human peripheral monocytes in part via suppression of monocyte chemoattractant protein-1 expression

(2008) Hiroyuki Hounoki et al.   BONE

Pioglitazone and dexamethasone induce adipogenesis in D1 bone marrow stromal cell line, but not through the peroxisome proliferator-activated receptor-γ pathway

(2008) Shao-Hung Hung et al.   LIFE SCIENCES

The Bone-Adipose Axis in Obesity and Weight Loss

(2008) J. Gómez-Ambrosi et al.   OBESITY SURGERY

Pathogenesis of Age-Related Osteoporosis: Impaired Mechano-Responsiveness of Bone Is Not the Culprit

(2008) Olli V. Leppänen et al.   PLoS One